Oric Pharmaceuticals, Inc.
ORIC evidence brief
What we can confirm
- BioSniper Score:
- 5.2 / 10
- Market Cap:
- $1.30B
- Lead Asset:
- enozertinib (Phase 1)
What it means
What to watch
Prepared research question
What matters most for ORIC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ORIC
Oric Pharmaceuticals (ORIC) is a clinical-stage biotech company developing precision oncology therapies for prostate and lung cancers, with two late-stage programs—rinzimetostat (ORIC-944) and enozertinib (ORIC-114)—and a cash position of $37.5M as of 2026-06-30 [sec].
Key risk: Cash runway uncertainty
BioSniper Score
Based on 4 of 6 signals
Market Cap
$1.30B
Cash Runway
—
Lead Asset
enozertinib (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Oric Pharmaceuticals, Inc..
Oric Pharmaceuticals (ORIC) is a clinical-stage biotech company developing precision oncology therapies for prostate and lung cancers, with two late-stage programs—rinzimetostat (ORIC-944) and enozertinib (ORIC-114)—and a cash position of $37.5M as of 2026-06-30 [sec].
- Lead program rinzimetostat (ORIC-944) entered a global Phase 3 trial (Himalayas-1) in metastatic castration-resistant prostate cancer as of August 2026 [news · 2026-09-15].
- Second program enozertinib (ORIC-114) is a brain-penetrant EGFR inhibitor for non-small cell lung cancer, with a Phase 1b combination study with amivantamab underway [news · 2026-01-16].
- Cash & equivalents were $37.5M as of 2026-06-30, down from $387.6M in cash and investments reported in Q2 2026 [sec] [news · 2026-09-15].
- Net loss for the six months ended June 30, 2026, was $77.3M, and the company has incurred significant accumulated losses since inception [sec_mda · as of 2026-08-03].
- In August 2025, the company raised $244M gross proceeds through a private placement and ATM issuances, and subsequently concluded anticipated ATM facility usage [news · 2025-08-13].
What works
- Two late-stage clinical programs (rinzimetostat and enozertinib) are advancing, with rinzimetostat in a Phase 3 trial and enozertinib in Phase 1b combination studies, indicating pipeline maturity [news · 2026-09-15] [news · 2026-01-16].
- The company reported potentially best-in-class clinical efficacy and safety data from the Phase 1b trial of rinzimetostat in combination with AR inhibitors for mCRPC [news · 2025-08-13].
- Strong investor interest was demonstrated by a $244M capital raise from top-tier healthcare specialist investors in 2025 [news · 2025-08-13].
- A strategic pipeline prioritization in August 2025 focused resources on the two lead programs, reducing preclinical research and discovery spending [sec_mda · as of 2026-08-03].
What to weigh
- Cash & equivalents have declined sharply from $387.6M (mid-2026) to $37.5M as of 2026-06-30, suggesting a high burn rate [news · 2026-09-15] [sec].
- Net loss for the first half of 2026 was $77.3M, and the company has incurred significant accumulated losses since inception, with no approved products generating revenue [sec_mda · as of 2026-08-03].
- The company faces all standard risks of pharmaceutical development, including unforeseen expenses, delays, and regulatory hurdles, and expects expenses to increase as programs advance [sec_mda · as of 2026-08-03].
- The strategic pipeline prioritization eliminated the discovery research group, reducing the company's early-stage pipeline and future candidate flow [sec_mda · as of 2026-08-03].
From the filings
Quoted directly from source documents.
Rinzimetostat entered a global Phase 3 trial in August 2026.
“The company started Himalayas-1, a global Phase 3 trial of its lead prostate cancer drug rinzimetostat”
News · September 15, 2026
Cash and investments were $387.6 million as of Q2 2026.
“while holding $387.6 million in cash and investments to fund the effort”
News · September 15, 2026
Net loss for the six months ended June 30, 2026, was $77.3 million.
“Our net loss for the six months ended June 30, 2026, was $77.3 million”
SEC MD&A · August 3, 2026
The company raised $244 million in gross proceeds from a private placement and ATM issuances in 2025.
“Strengthened cash position with $244 million gross proceeds from top-tier healthcare specialist investors across $125 million private placement financing and $119 million ATM issuances”
News · August 13, 2025
Catalyst timeline
- 2026-08-03 · Phase 3 start for rinzimetostat (ORIC-944) in combination with darolutamide — A global Phase 3 trial (Himalayas-1) began in August 2026, evaluating rinzimetostat plus darolutamide in metastatic castration-resistant prostate cancer.
- 2025-02-27 · Phase 1b start for enozertinib (ORIC-114) in combination with amivantamab — A Phase 1b study of ORIC-114 in combination with amivantamab in patients with EGFR Exon20 insertion mutant NSCLC was initiated.
- 2022-06-01 · Phase 1 start for ORIC-944 as single agent or in combination — An open-label Phase 1/1b study of ORIC-944 in metastatic prostate cancer began in June 2022.
- 2022-03-10 · Phase 1/2 start for ORIC-114 as single agent or in combination — A Phase 1/2 study of ORIC-114 in advanced solid tumors with EGFR or HER2 alterations started in March 2022.
Risks & what to watch (4)›
Key risks
- Cash runway uncertainty — Cash dropped from $387.6M to $37.5M in a few months; high burn rate may require further financing [sec] [news · 2026-09-15].
- No approved products — Company has no marketed drugs; all revenue depends on successful clinical and regulatory outcomes [sec_mda · as of 2026-08-03].
- Clinical and regulatory risks — Phase 3 and Phase 1b trials may face delays, safety issues, or failure to meet endpoints [sec_mda · as of 2026-08-03].
- Reduced early-stage pipeline — Elimination of discovery research group limits future pipeline replenishment [sec_mda · as of 2026-08-03].
What to watch
- Initiation and enrollment progress of the Himalayas-1 Phase 3 trial for rinzimetostat [news · 2026-09-15].
- Data readouts from the enozertinib Phase 1b combination study with amivantamab [news · 2026-01-16].
- Cash burn rate and any new financing or partnership announcements given the low cash position [sec].
- Regulatory interactions and potential filing plans for either lead program [sec_mda · as of 2026-08-03].
Sources: Catalysts · News · SEC MD&A · Generated October 7, 2026 · How we verify sources →
Run Oric Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Oric Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
182
Total value held
$1.43B
| Holder | Shares | Value |
|---|---|---|
| nextech invest, ltd. | 7,162,637 | $90.8M |
| ecor1 capital, llc | 6,728,116 | $85.2M |
| blackrock, inc. | 5,984,552 | $75.8M |
| viking global investors lp | 5,824,533 | $73.8M |
| sr one capital management, lp | 4,514,929 | $58.5M |
| pfizer inc | 4,780,401 | $57.7M |
| alkeon capital management llc | 4,504,096 | $57.1M |
| venrock adviser, llc | 4,319,765 | $54.7M |
| nea management company, llc | 4,118,621 | $52.2M |
| state street corp | 3,702,196 | $46.9M |
Showing top 10 of 182 institutional holders of Oric Pharmaceuticals, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 21.5%
- Days to cover
- 9.2
- Shares short
- 22,009,149
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ORIC short interestGovernance
Frequently asked questions
What is the AI investment thesis for Oric Pharmaceuticals, Inc.?
Oric Pharmaceuticals (ORIC) is a clinical-stage biotech company developing precision oncology therapies for prostate and lung cancers, with two late-stage programs—rinzimetostat (ORIC-944) and enozertinib (ORIC-114)—and a cash position of $37.5M as of 2026-06-30 [sec].
What is Oric Pharmaceuticals, Inc.'s lead drug candidate?
Oric Pharmaceuticals, Inc.'s most advanced tracked candidate is enozertinib (Phase 1) for Non-small cell lung cancer (NSCLC) with EGFR exon 20 and EGFR atypical mutations.
Who is the CEO of Oric Pharmaceuticals, Inc.?
Dr. Jacob M. Chacko M.B.A., M.D. is the chief executive officer of Oric Pharmaceuticals, Inc. (ORIC).
Where is Oric Pharmaceuticals, Inc. headquartered?
Oric Pharmaceuticals, Inc. (ORIC) is headquartered in South San Francisco, CA, United States.
What therapeutic areas does Oric Pharmaceuticals, Inc. focus on?
Oric Pharmaceuticals, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.